Celgene's psoriasis drug apremilast performs well in trial

03/4/2013 | Reuters

More psoriasis patients who took Celgene's experimental drug apremilast experienced improvements in symptoms compared with patients who took a placebo, a late-stage trial found. Celgene plans to submit the drug for FDA approval this year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD